Vasciaveo, A., Arriaga, J. M., de Almeida, F. N., Zou, M., Douglass, E. F., Picech, F., Shibata, M., Rodriguez-Calero, A., de Brot, S., Mitrofanova, A., Chua, C. W., Karan, C., Realubit, R., Pampou, S., Kim, J. Y., Afari, S. N., Mukhammadov, T., Zanella, L., Corey, E., … Abate-Shen, C. (2022). OncoLoop: A Network-Based Precision Cancer Medicine Framework. Cancer Discovery, 13(2), 386–409. https://doi.org/10.1158/2159-8290.cd-22-0342

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223

Ilozumba, M. N., Yao, S., Llanos, A. A. M., Omilian, A. R., Zhang, W., Datta, S., Hong, C.-C., Davis, W., Khoury, T., Bandera, E. V., Higgins, M., Ambrosone, C. B., & Cheng, T.-Y. D. (2022). mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients. Discover Oncology, 13(1). https://doi.org/10.1007/s12672-022-00497-y

Cordo’, V., Meijer, M. T., Hagelaar, R., de Goeij-de Haas, R. R., Poort, V. M., Henneman, A. A., Piersma, S. R., Pham, T. V., Oshima, K., Ferrando, A. A., Zaman, G. J. R., Jimenez, C. R., & Meijerink, J. P. P. (2022). Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-28682-1

de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, S. A., Rosenquist, R., Rossi, D., Salaverria, I., Steidl, C., Treon, S. P., Zelenetz, A. D., … Scott, D. W. (2022). Genomic profiling for clinical decision making in lymphoid neoplasms. Blood, 140(21), 2193–2227. https://doi.org/10.1182/blood.2022015854

Molina, J. C., Chinnabhandar, V., Fabrizio, V. A., Kunicki, M., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Verneris, M. R., Myers, G. D., Karras, N., Baggott, C., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., Baumeister, S. H. C., … Smith, S. M. (2022). Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups. Blood, 140(Supplement 1), 10386–10388. https://doi.org/10.1182/blood-2022-165951

Koff, J. L., Kositsky, R., Jaye, D. L., Churnetski, M. C., Baird, K., O’Leary, C. B., Flowers, C. R., Leppa, S., Karjalainen-Lindsberg, M.-L., Li, S., Xu, J., Pedersen, M. Ø., Gang, A. O., Naresh, K. N., Leeman-Neill, R. J., Au Yeung, K. H. R., Qureishi, H. N., Iqbal, J., Chapman-Fredricks, J. R., … Cohen, J. B. (2022). Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma. Blood, 140(Supplement 1), 3500–3503. https://doi.org/10.1182/blood-2022-168002

Van Egeren, D., Kohli, K., Warner, J. L., Bedard, P. L., Riely, G., Lepisto, E., Schrag, D., LeNoue-Newton, M., Catalano, P., Kehl, K. L., Michor, F., Fiandalo, M., Foti, M., Khotskaya, Y., Lee, J., Peters, N., Sweeney, S., Abraham, J., … Walther, Z. (2022). Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-21448-1

Castro, M., Iwamoto, F., Ahluwalia, M., Usmani, S., Kumar, A., Kapoor, S., Suseela, R. P., Kulkarni, S., Mohanty, J., Shyamasundar, V., Ghosh, A., Prasad, N., Patil, M., Choudhury, S. R., Chauhan, J., Sauban, M., Joseph, V., Kumari, P., Mitra, U., … Basu, S. (2022). EPCO-06. THE IMPACT OF MISMATCH REPAIR DEFICIENCY (MMRD) ON SURVIVAL OF TEMOZOLOMIDE (TMZ)-TREATED PATIENTS WITH MGMT METHYLATED (M-MGMT) GLIOBLASTOMA (GBM): A CELLWORKS COMPUTATIONAL BIOSIMULATION PILOT STUDY. Neuro-Oncology, 24(Supplement_7), vii116–vii117. https://doi.org/10.1093/neuonc/noac209.441

Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., Vattakalam, R. M., Ross, A., Mills, M., Suarez, C. J., Davis, T., Edwards, R., Boisen, M., Sawyer, S., Wu, H.-T., Dashner, S., Aushev, V. N., George, G. V., Malhotra, M., … Ford, J. M. (2022). Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology, 167(2), 334–341. https://doi.org/10.1016/j.ygyno.2022.09.004

Liao, C.-Y., Johnson, B., Spira, A., Carbone, D., Henick, B., Overman, M., Polite, B., Roychowdhury, S., Mahipal, A., Ahn, D., Johnson, M., Schenk, D., Bae, K., Davis, M., Jooss, K., Ferguson, A., & Solomon, B. (2022). 660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen. Regular and Young Investigator Award Abstracts, A691–A691. https://doi.org/10.1136/jitc-2022-sitc2022.0660

Ellingson, B., Wen, P. Y., Chang, S., van den Bent, M., Vogelbaum, M., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A., Gilbert, M., de Groot, J., Weller, M., Galanis, E., & Cloughesy, T. (2022). NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS). Neuro-Oncology, 24(Supplement_7), vii172–vii173. https://doi.org/10.1093/neuonc/noac209.660

Flerlage, J. E., Birz, S., Castellino, S. M., Appel, B., Furner, B., Graglia, L., Henderson, T. O., Hodgson, D., Hoppe, B. S., Kahn, J., Keller, F. G., Kessel, S., Li, C., Li, M., Lucas, J., Mccarten, K., Metzger, M., Milgrom, S., Parsons, S. K., … Kelly, K. M. (2022). P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL. HemaSphere, 6, 39–40. https://doi.org/10.1097/01.hs9.0000890912.56229.80

Miller, A. M., Szalontay, L., Bouvier, N., Hill, K., Ahmad, H., Rafailov, J., Lee, A. J., Rodriguez-Sanchez, M. I., Yildirim, O., Patel, A., Bale, T. A., Benhamida, J. K., Benayed, R., Arcila, M. E., Donzelli, M., Dunkel, I. J., Gilheeney, S. W., Khakoo, Y., Kramer, K., … Karajannis, M. A. (2022). Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. Neuro-Oncology, 24(10), 1763–1772. https://doi.org/10.1093/neuonc/noac035

Laise, P., Bosker, G., Califano, A., & Alvarez, M. J. (2022). A Patient‐to‐Model‐to‐Patient (PMP) Cancer Drug Discovery Protocol for Identifying and Validating Therapeutic Agents Targeting Tumor Regulatory Architecture. Current Protocols, 2(9). Portico. https://doi.org/10.1002/cpz1.544

Pass, H., Kim, A. W., Felip, E., Shu, C. A., Ferris, A., Frueh, M., Gitlitz, B. J., Troutman, S., Petrek, H., Liu, X., Hsu, J., Patil, N., & Meng, R. D. (2022). 970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC. Annals of Oncology, 33, S990–S991. https://doi.org/10.1016/j.annonc.2022.07.1096

Lai, D., Gade, M., Yang, E., Koh, H. Y., Lu, J., Walley, N. M., Buckley, A. F., Sands, T. T., Akman, C. I., Mikati, M. A., McKhann, G. M., Goldman, J. E., Canoll, P., Alexander, A. L., Park, K. L., Von Allmen, G. K., Rodziyevska, O., Bhattacharjee, M. B., Lidov, H. G. W., … Heinzen, E. L. (2022). Somatic variants in diverse genes leads to a spectrum of focal cortical malformations. Brain, 145(8), 2704–2720. https://doi.org/10.1093/brain/awac117

Dar, P., Jacobsson, B., MacPherson, C., Egbert, M., Malone, F., Wapner, R. J., Roman, A. S., Khalil, A., Faro, R., Madankumar, R., Edwards, L., Haeri, S., Silver, R., Vohra, N., Hyett, J., Clunie, G., Demko, Z., Martin, K., Rabinowitz, M., … Norton, M. E. (2022). Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. American Journal of Obstetrics and Gynecology, 227(2), 259.e1-259.e14. https://doi.org/10.1016/j.ajog.2022.01.019

de Prisco, N., Botta, S., Lee, W., Rezazadeh, S., Chemiakine, A., & Gennarino, V. A. (2022). Determining the effects of loss of function mutations in human cell lines. STAR Protocols, 3(2), 101232. https://doi.org/10.1016/j.xpro.2022.101232

Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V., Ferraro, R. A., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W., Drilon, A., Chi, P., Angelo, S. P. D., Dickson, M. A., Keohan, M. L., Kelly, C. M., Agulnik, M., Chawla, S. P., Choy, E., … Jin, D. X. (2022). Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-30496-0

Hill, K., Miller, A. M., Li, B. K., Bouvier, N., Li, S., Alano, T., Doe-Tetteh, S., Huereca, C., DiNapoli, S., Lee, A., Szalontay, L., Riviere-Cazaux, C., Burns, T. C., Haque, S., Bale, T., Benhamida, J., Dogan, S., Vanderbilt, C., Ross, D., … Karajannis, M. (2022). PATH-16. Noninvasive diagnosis of gliomas through CSF cfDNA sequencing in pediatric and adolescent and young adult (AYA) patients. Neuro-Oncology, 24(Supplement_1), i162–i162. https://doi.org/10.1093/neuonc/noac079.600

Mukherjee, S., Ali, A. M., Murty, V. V., & Raza, A. (2022). Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells. Medical Oncology, 39(6). https://doi.org/10.1007/s12032-022-01652-9

Akkari, Y. M. N., Baughn, L. B., Dubuc, A. M., Smith, A. C., Mallo, M., Dal Cin, P., Diez Campelo, M., Gallego, M. S., Granada Font, I., Haase, D. T., Schlegelberger, B., Slavutsky, I., Mecucci, C., Levine, R. L., Hasserjian, R. P., Solé, F., Levy, B., & Xu, X. (2022). Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 139(15), 2273–2284. https://doi.org/10.1182/blood.2021014309

Rahimi, A., Simmons, A., Kim, D. N., Leitch, M., Haas, J., Gu, X., Ahn, C., Gao, A., Spangler, A., Morgan, H. E., Goudreau, S., Seiler, S., Farr, D., Wooldridge, R., Haley, B., Bahrami, S., Neufeld, S., Mendez, C., Alluri, P., … Timmerman, R. D. (2022). Preliminary Results of Multi-Institutional Phase 1 Dose Escalation Trial Using Single-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer. International Journal of Radiation Oncology*Biology*Physics, 112(3), 663–670. https://doi.org/10.1016/j.ijrobp.2021.10.010

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275

Das, A., Sudhaman, S., Morgenstern, D., Coblentz, A., Chung, J., Stone, S. C., Alsafwani, N., Liu, Z. A., Karsaneh, O. A. A., Soleimani, S., Ladany, H., Chen, D., Zatzman, M., Cabric, V., Nobre, L., Bianchi, V., Edwards, M., Sambira Nahum, L. C., Ercan, A. B., … Tabori, U. (2022). Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 28(1), 125–135. https://doi.org/10.1038/s41591-021-01581-6

Thomas, A., Kwon, W., Tehranifar, P., Sugahara, K., Schrope, B., Chabot, J., Genkinger, J., & Kluger, M. (2022). Barriers to Standard of Care in the United States: Trends in the Treatment of Locally Advanced Pancreatic Cancer in the Modern Era of Chemotherapy. HPB, 24, S36. https://doi.org/10.1016/j.hpb.2022.05.071

Wang, Z., Fan, X., Shen, Y., Pagadala, M. S., Signer, R., Cygan, K. J., Fairbrother, W. G., Carter, H., Chung, W. K., & Huang, K. (2021). Non-cancer-related pathogenic germline variants and expression consequences in ten-thousand cancer genomes. Genome Medicine, 13(1). https://doi.org/10.1186/s13073-021-00964-1

Rodriguez, D. A., Yang, J., Durante, M. A., Shoushtari, A. N., Moschos, S. J., Wrzeszczynski, K. O., Harbour, J. W., & Carvajal, R. D. (2021). Multiregional genetic evolution of metastatic uveal melanoma. Npj Genomic Medicine, 6(1). https://doi.org/10.1038/s41525-021-00233-5

Ahuno, S. T., Doebley, A.-L., Ahearn, T. U., Yarney, J., Titiloye, N., Hamel, N., Adjei, E., Clegg-Lamptey, J.-N., Edusei, L., Awuah, B., Song, X., Vanderpuye, V., Abubakar, M., Duggan, M., Stover, D. G., Nyarko, K., Bartlett, J. M. S., Aitpillah, F., Ansong, D., … Biritwum, R. (2021). Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. Npj Precision Oncology, 5(1). https://doi.org/10.1038/s41698-021-00219-7

Canterbury, C. R., Fernandes, H., Crapanzano, J. P., Murty, V. V., Mansukhani, M. M., Shu, C. A., Szabolcs, M., & Saqi, A. (2021). ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing. JTO Clinical and Research Reports, 2(10), 100223. https://doi.org/10.1016/j.jtocrr.2021.100223

Love, C., Pillai, R., Ondrejka, S. L., Bhagat, G., Chadburn, A., McKinney, M., Koff, J. L., Soliman, D. S., Czader, M., Louissaint, A., Li, S., Ong, C. K., Behdad, A., Evens, A. M., Natkunam, Y., Norgaard, P. H., Leppa, S., Tse, E., Chapman, J. R., … Dave, S. (2021). The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas. Blood, 138(Supplement 1), 2213–2213. https://doi.org/10.1182/blood-2021-151346

Paolino, J. D., Harris, M. H., Stevenson, K. E., Koch, V., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Kirsch, Ii., Michon, B., Place, A. E., Tran, T. H., Welch, J. J. G., & Silverman, L. B. (2021). Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001. Blood, 138(Supplement 1), 3485–3485. https://doi.org/10.1182/blood-2021-152369

Blomquist, M., Noviello, T., D’Angelo, F., Sereduk, C., Rabichow, B., Miller, A., Marin, B.-M., White, F., Sarkaria, J., Lasorella, A., Iavarone, A., Ceccarelli, M., & Tran, N. (2021). CSIG-08. ABT-414 RESISTANT GBM TUMORS HARBOR THE TEK S466I MUTATION AND EXHIBIT INCREASED STEMNESS. Neuro-Oncology, 23(Supplement_6), vi34–vi35. https://doi.org/10.1093/neuonc/noab196.134

Katona, B. W., Long, J. M., Ahmad, N. A., Attalla, S., Bradbury, A. R., Carpenter, E. L., Clark, D. F., Constantino, G., Das, K. K., Domchek, S. M., Dudzik, C., Ebrahimzadeh, J., Ginsberg, G. G., Heiman, J., Kochman, M. L., Maxwell, K. N., McKenna, D. B., Powers, J., Shah, P. D., … Rustgi, A. K. (2021). EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 14(11), 1033–1040. https://doi.org/10.1158/1940-6207.capr-21-0161

Reinfeld, B., Madden, M., Wolf, M., Cubas, A. de, Haake, S., Hongo, R., Axelrod, M., Bader, J., Obradovic, A., Greenwood, D., Ye, X., Balko, J., Beckermann, K., Vincent, B., Rini, B., Drake, C., Rathmell, J., & Rathmell, W. (2021). 906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme. Regular and Young Investigator Award Abstracts, A951–A951. https://doi.org/10.1136/jitc-2021-sitc2021.906

Rahimi, A. S., Kim, D. N., Leitch, M., Gu, X., Haas, J. A., Ahn, C., Spangler, A., Neufeld, S., Bahrami, S., Goudreau, S., Seiler, S., Farr, D., Wooldridge, R., Haley, B., Alluri, P. G., Nwachukwu, C. R., Rao, R., & Timmerman, R. D. (2021). Early Follow-Up of Multi-Institutional Trial of Phase I Dose Escalation Using Single Fraction Stereotactic Partial Breast Irradiation (S-PBI) for Early-Stage Breast Cancer. International Journal of Radiation Oncology*Biology*Physics, 111(3), e228. https://doi.org/10.1016/j.ijrobp.2021.07.782

Saleh, T., El-Sadoni, M., Alhesa, A., Awad, H., Jaradat, M., Al-Hazaimeh, M., Dawoud, R., Mryyian, A., & Azab, B. (2021). Expression of Senescence and Apoptosis Biomarkers in Synchronous Bilateral Breast Cancer: A Case Report. Current Oncology, 28(5), 3836–3845. https://doi.org/10.3390/curroncol28050327

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. A., Girard, N., Viteri, S., Han, J.-Y., Kim, S.-W., Lee, C. K., Sabari, J. K., Spira, A. I., Yang, T.-Y., Kim, D.-W., Lee, K. H., Sanborn, R. E., Trigo, J., Goto, K., Lee, J.-S., … Cho, B. C. (2021). Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 39(30), 3391–3402. https://doi.org/10.1200/jco.21.00662

He, Y., Rivera, J., Diossy, M., Duan, H., Bowman-Colin, C., Reed, R., Jennings, R., Novak, J., Tran, S. V., Cohen, E. F., Szuts, D., Giobbie-Hurder, A., Bronson, R. T., Bass, A. J., Signoretti, S., Szallasi, Z., Livingston, D. M., & Pathania, S. (2021). BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proceedings of the National Academy of Sciences, 118(41). https://doi.org/10.1073/pnas.2108421118

Bondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Mcginniss, J., Pouliot, J., Lee, S., Seebach, F., Lowy, I., Gullo, G., & Rietschel, P. (2021). FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1. Journal of Thoracic Oncology, 16(10), S951. https://doi.org/10.1016/j.jtho.2021.08.217

Dinh, K. N., Jaksik, R., Corey, S. J., & Kimmel, M. (2021). Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data. Computational and Systems Oncology, 1(3). Portico. https://doi.org/10.1002/cso2.1026

Peters, S., Rizvi, N. A., Kuziora, M., Lai, Z., Shrestha, Y., Dey, A., Barrett, J. C., Scheuring, U., Poole, L., Abbosh, C., Raja, R., & Hellmann, M. D. (2021). 1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial. Annals of Oncology, 32, S989–S990. https://doi.org/10.1016/j.annonc.2021.08.1866